Company Overview and News

1
GNC: 2018 Consensus Estimates Appear High

2018-04-15 seekingalpha
We believe current consensus estimates for the full year don't fully reflect GNC's debt refinancing and the company may fall short of expectations.
Upvote Downvote

 
GNC Holdings: Clarification On The FDA White Paper And Caffeine Warnings

2018-04-15 seekingalpha
This is white paper that is non binding and it isn't targeting GNC, Vitamin Shoppe, or Bodybuilding.com sports nutrition products.
Upvote Downvote

2
GNC / GNC Holdings, Inc. DEFA 14A

2018-04-10 sec.gov
DEFA14A 1 gnc-defa14a_052317.htm ADDITIONAL MATERIAL
Upvote Downvote

2
GNC / GNC Holdings, Inc. DEF 14A

2018-04-10 sec.gov
UNITED STATES
Upvote Downvote

 
What's in Store for GNC Holdings (GNC) This Earnings Season?

2018-04-10 zacks
GNC Holdings, Inc. (GNC - Free Report) is scheduled to report first-quarter 2018 results on Apr 26, before the opening bell.
Upvote Downvote

 
Bespoke's Most Volatile Stocks On Earnings: April 2018 Edition

2018-04-10 seekingalpha
The first-quarter earnings season began Monday. With the stock market struggling lately, there seem to be a lot of bulls hanging their hopes on earnings strength to help pull the market out of correction territory.
Upvote Downvote

 
Bespoke’s Most Volatile Stocks on Earnings: April 2018 Edition | Bespoke Investment Group

2018-04-09 bespokepremium
The first quarter earnings season begins today. With the stock market struggling lately, there seem to be a lot of bulls hanging their hopes on earnings strength to help pull the market out of correction territory.
Upvote Downvote

 
GNC Holdings Partners Rapid Nutrition, Forays in Australia

2018-04-09 zacks
Moving ahead strongly with its focus on international expansion, GNC Holdings, Inc. (GNC - Free Report) has recently announced plans to foray in Australia. To that end, the company has already entered into a master franchise agreement with Rapid Nutrition.
Upvote Downvote

 
National Oilwell Varco: A Dividend Cut Success Story

2018-03-28 seekingalpha
Last year I wrote an article about GNC Holdings (GNC) and my covered call option writing strategy to exit my position without getting harmed post dividend cut. That article can be read here. Although many commenters applauded my strategy, many did not like it either. Many investors felt it was too risky to “wait” to exit out of my GNC position due to the rapid price movement and wild volatility. Every time GNC reported earnings, the stock price either dropped by 20% or rose by 20% due to the wild retail industry swings at the time.
Upvote Downvote

1
GNC / GNC Holdings, Inc. DEF 14A

2018-03-26 sec.gov
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Upvote Downvote

 
GNC / GNC Holdings, Inc. 8-K (Current Report)

2018-03-21 sec.gov
Document UNITED STATES
Upvote Downvote

 
Why Is GNC Holdings (GNC) Up 1.4% Since Its Last Earnings Report?

2018-03-15 zacks
It has been about a month since the last earnings report for GNC Holdings, Inc. (GNC - Free Report) . Shares have added about 1.4% in that time frame.
Upvote Downvote

1
The $3.8 Billion Crowded Short Natural Gas E&P Trade

2018-03-12 seekingalpha
Using the February 28 short interest data, and today's stock prices, there's a $3.8 billion (bet) short on the gassy E&P names.
Upvote Downvote

1
Seanergy Maritime: Has Substance But Remains Speculative

2018-03-12 seekingalpha
In the right market conditions and correct management execution, Seanergy can be one of the most attractive stocks in dry bulk.
Upvote Downvote

 
GNC Holdings Expands in India, Boosts International Business

2018-03-12 zacks
Keeping in line with the strategy to fortify its hold on high-potential geographical regions, GNC Holdings, Inc. (GNC - Free Report) recently announced plans to expand presence in India. In India, the company operates in collaboration with the master franchise partner — Guardian Healthcare Services Pvt. Ltd.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 36191G107